国家银屑病基金会医学委员会:斑块状银屑病治疗目标
美国国家银屑病基金会采用德尔菲法,组织25名银屑病专家建立斑块状银屑病的治疗目标。最常用评估工具为体表面积(BSA),新疗法启动后3个月评估应答,可接受应答为BSA≤3%或较基线改善≥75%,目标应答为BSA≤1%;维持期每6个月评估,目标为BSA≤1%。
要点
- 新疗法启动后3个月评估应答,目标为BSA≤1%。
- 3个月可接受应答为BSA≤3%或较基线改善≥75%。
- 维持期每6个月评估,目标为BSA≤1%。
核心结论
- 确立斑块状银屑病治疗目标有助于医患定期评估应答并个体化权衡获益与风险。
研究设计与样本
- 国家银屑病基金会采用德尔菲法开展共识建设研究,共25名银屑病专家参与,流程包括文献回顾、预德尔菲问题选择与输入、4轮德尔菲。
主要发现
- 最受偏好的评估工具为体表面积(BSA)。
- 新疗法启动后最受偏好的评估时间为3个月。
- 维持期最受偏好的评估频率为每6个月一次。
关键数值与推荐
- 新疗法启动后3个月可接受应答为BSA≤3%或较基线改善≥75%。
- 新疗法启动后3个月目标应答为BSA≤1%。
- 维持期每6个月评估的目标应答为BSA≤1%。
临床怎么用
- 临床可依据3个月和每6个月的时间点,用BSA评估银屑病治疗应答并设定目标。
局限性
- BSA在实际中可行,但未涵盖健康相关生活质量、费用和副作用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An urgent need exists in the United States to establish treatment goals in psoriasis. OBJECTIVE: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice. METHODS: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds. RESULTS: A total of 25 psoriasis experts participated in the Delphi process. The most preferred instrument was body surface area (BSA). The most preferred time for evaluating patient response after starting new therapies was at 3 months. The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline. The target response at 3 months postinitiation was BSA 1% or less. During the maintenance period, evaluation every 6 months was most preferred. The target response at every 6 months maintenance evaluation is BSA 1% or less. LIMITATIONS: Although BSA is feasible in practice, it does not encompass health-related quality of life, costs, and risks of side effects. CONCLUSION: With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.
引用
- Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2016. PMID: 27908543. doi:10.1016/j.jaad.2016.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。